DETAILED ACTION
Notice of Pre-AIA or AIA Status
1. The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Response to Amendment
2. The amendments to the claims filed on December 26, 2025 have been fully considered. The amendments are sufficient to overcome the prior art rejection over RN 1017-06-7 which is withdrawn.
3. Pursuant MPEP 803.02 the search and examination was extended. Prior art was found that anticipates the amended Markush claims with respect to a nonelected species. Therefore, the Markush claims were rejected and claims to nonelected species were held withdrawn from further consideration. The claims were further searched to the extent of the nonelected species shown below.
Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
4. Claim(s) 1-3, 6, 7 and 10-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 21282-90-6 (
PNG
media_image1.png
88
254
media_image1.png
Greyscale
). The reference has a date of 1984 which antedates the present claims having an effective filing date of August 2, 2018. The reference teaches compound and pharmaceutical composition in water, wherein the compound corresponds to the present claims in the following manner: R1=R2=R6=R7=H; R3=NR6R7.
5. Claim(s) 1-3, 6, 7 and 10-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by RN 36735-37-2 (
PNG
media_image2.png
94
294
media_image2.png
Greyscale
). The reference has a date of 1984 which antedates the present claims having an effective filing date of August 2, 2018. The reference teaches compound and pharmaceutical composition in water, wherein the compound corresponds to the present claims in the following manner: R1=R2=H; R3=morpholin-4-yl.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUN JAE YOO whose telephone number is (571)272-9074. The examiner can normally be reached Mon-Fri 8-5.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/SUN JAE YOO/Primary Examiner, Art Unit 1621
Prosecution Insights